Stay connected with Necrobiosis Lipoidica study info
Publications
Stay up to date on our latest publications and findings.
PCS12852 is a novel, potent, and highly selective 5-HT4 receptor agonist for treating Gastrointestinal (GI) mobility disorders. These GI disorders may take many forms, including chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia, and gastroparesis.
Other 5-HT4 receptor antagonists have been successful in treating GI motility disorders. However, these often have less 5-HT4 selectivity and are associated with cardiovascular side effects due to the drugs binding to other receptors. In contrast, PCS12852 has been shown in clinical trials to increase GI function with no serious adverse effects.
On August 19, 2020, we acquired an exclusive license from Yuhan Corporation to develop, manufacture, and commercialize PCS12852 globally except for South Korea.
PCS12852 is a more potent and selective alternative to existing 5HT4 agonists and carries a lower risk of cardiovascular side effects.
Gastroparesis is a gastric mobility disorder that affects the nerves and muscles of the stomach, leading to postprandial fullness, nausea, vomiting, and bloating. It is the most common cause of prolonged hospital stays following GI surgery, leading to increased healthcare costs. Current treatments for gastroparesis carry an increased risk of severe side effects such as heart attacks, neurological toxicity, and suicidal ideation. Having shown no serious adverse effects in clinical studies, PCS12852 may be a promising new treatment for gastroparesis.
Market1
1. Source: Gastroparesisclinic.org; Swinburne University of Technology